OasisLMS

1. Describe how biomarkers are essential to precision oncology in providing information to stratify patients based on diagnosis, prognosis, and therapy response. Although no biomarker-driven therapies are approved for mHSPC, explore personalized approaches to improve outcomes earlier in the disease, before it progresses to mCRPC.

2. Evaluate the potential of PTEN deficiency or loss as a significant prognostic biomarker for PI3K/AKT pathway activation in metastatic prostate cancer. Identify the value of routinely testing all mHSPC tumors for PTEN deficiency to find patients with more aggressive, high-risk disease, which can potentially guide earlier treatment strategies that may delay progression to mCRPC and may improve survival outcomes.